JNJ stock is in a distribution period from its $180 peak. However, the weekly chart displays 9 consecutive bearish 1-W candles. The RSI is also in the oversold region. In the short-term the price could rise or drift sideways between $150 and $155. The price is likely to continue moving down to support levels near the $145/$135 levels. The downtrend does not appear to be slowing down and investors should not adopt a bottom-fishing mindset. Traders can wait for a $160 retrace before they sell.
Johnson & Johnson, (JNJ), has a long history of being a trusted name in the medical and pharmaceutical device industries. JNJ has over 135+ years of experience. This makes it an innovator and leader.
JNJ’s diverse product line is one of its most distinctive characteristics. It includes medical devices, pharmaceuticals, and consumer-health items. This has allowed the company weather market fluctuations and economic downturns with ease, making it an attractive investment for shareholders.
JNJ’s drug division is a leading player in the industry. The company places great emphasis on research, development and quality control. They invest heavily in R&D which has resulted in many groundbreaking drugs such as Remicade, Stelara and other life-changing treatments for patients. JNJ boasts a vast pipeline of drugs that are in development, which will assure its continued success.
JNJ, a leader in medical device, has extensive expertise in surgical equipment, orthopedics and cardiovascular devices. Their devices have revolutionized the field of surgery by making procedures less invasive, and improving patient outcomes. JNJ is a pioneer in patient-centric design and has contributed greatly to the success of this sector.
JNJ Consumer Health Division is a household staple. Products like Tylenol or Band-Aids have become household staples. JNJ’s strong brand reputation has enabled it to achieve great successes.
JNJ’s ability to diversify, invest in R&D, as well as its patient-centric design, make it a top investment candidate in the medical device and pharmaceutical industry. JNJ will be an industry leader in many areas for many years, and I believe this is based on my experience as a stock market expert.
